Basilea News Basilea News en Thu, 27 Apr 2017 16:54:19 +0200 Thu, 27 Apr 2017 16:54:19 +0200 Chameleon CMS (Webmaster Webmaster) (Webmaster Webmaster) <![CDATA[Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections]]>
  • Initiation of ceftobiprole pivotal phase 3 clinical program under BARDA contract anticipated within the next three to six months
  • ]]>
    Fri, 21 Apr 2017 07:15:00 +0200
    <![CDATA[Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab]]>
  • BAL101553 targets tumor cell proliferation, adaptation to low oxygen and vascularization
  • Switch from weekly to daily oral dosing leads to reduced tumor anti-vascular activity while maintaining tumor growth inhibition
  • Combination with the anti-VEGF therapy bevacizumab shows enhanced anti-tumor response
  • ]]>
    Thu, 06 Apr 2017 07:15:00 +0200
    <![CDATA[Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors]]> Mon, 27 Feb 2017 07:15:00 +0100 <![CDATA[Basilea reports solid 2016 results and expects to double product sales in 2017]]>
  • Cresemba® launched by Basilea in first European countries and marketed together with Zevtera®/Mabelio®
  • Entered into distribution and license agreements covering more than 40 countries for both Cresemba and Zevtera/Mabelio
  • Product sales of CHF 7.1 million in Europe and CHF 7.3 million royalties received on 2016 Cresemba US sales
  • CHF 289 million cash and financial investments at year-end
  • Initiation of ceftobiprole clinical phase 3 development program under BARDA agreement anticipated mid-2017 to support potential future US regulatory filing
  • ]]>
    Mon, 20 Feb 2017 07:15:00 +0100
    <![CDATA[Basilea names new member of its Extended Management Committee]]> Thu, 29 Dec 2016 07:15:00 +0100 <![CDATA[Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients]]> Fri, 02 Dec 2016 07:15:00 +0100 <![CDATA[Basilea's antifungal Cresemba® (isavuconazole) launched in France]]> Tue, 15 Nov 2016 07:15:00 +0100 <![CDATA[Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries]]> Tue, 20 Sep 2016 07:15:00 +0200 <![CDATA[Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma]]>
  • Basilea grants Asahi Kasei Pharma exclusive license to develop and commercialize isavuconazole in Japan
  • Basilea eligible for upfront and milestone payments of up to CHF 67 million and double-digit royalties

  • ]]>
    Thu, 15 Sep 2016 07:15:00 +0200
    <![CDATA[Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America]]> Tue, 13 Sep 2016 07:15:00 +0200